DECAMP-1 and DECAMP-2 Trial Information

The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that includes Veterans Administration hospitals, military treatment facilities, and academic hospitals as clinical study sites.

The DECAMP-1 and DECAMP-2 studies, which began in 2013 and 2015 respectively, aim to improve early detection of lung cancer through noninvasive biomarkers and improved screening. These studies are funded by the Department of Defense Lung Cancer Research Program, Johnson and Johnson Inc., and Novartis Biomedical Research Institutes. Boston University in collaboration with the American College of Radiology® conducts the DECAMP studies.

DECAMP-1 Trial »   DECAMP-2 Trial »

DECAMP Case Registration

Newest Study: DECAMP-1 PLUS

DECAMP Lung Cancer Biomarker Research Study

The DECAMP-1 PLUS study will help researchers learn if biomarkers can help detect lung cancer earlier and increase the chances for a cure.

Visit website